{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:41:37Z","timestamp":1790660497130,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["W2412122"],"award-info":[{"award-number":["W2412122"]}]},{"name":"National Natural Science Foundation of China","award":["82200208"],"award-info":[{"award-number":["82200208"]}]},{"name":"National Natural Science Foundation of China","award":["8247012736"],"award-info":[{"award-number":["8247012736"]}]},{"name":"National Natural Science Foundation of China","award":["QZ23-6"],"award-info":[{"award-number":["QZ23-6"]}]},{"name":"National Natural Science Foundation of China","award":["QZ23-4"],"award-info":[{"award-number":["QZ23-4"]}]},{"name":"National Natural Science Foundation of China","award":["24ZXZSSS00050"],"award-info":[{"award-number":["24ZXZSSS00050"]}]},{"name":"National Natural Science Foundation of China","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}]},{"name":"National Natural Science Foundation of China","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["W2412122"],"award-info":[{"award-number":["W2412122"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["82200208"],"award-info":[{"award-number":["82200208"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["8247012736"],"award-info":[{"award-number":["8247012736"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["QZ23-6"],"award-info":[{"award-number":["QZ23-6"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["QZ23-4"],"award-info":[{"award-number":["QZ23-4"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["24ZXZSSS00050"],"award-info":[{"award-number":["24ZXZSSS00050"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}]},{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["W2412122"],"award-info":[{"award-number":["W2412122"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["82200208"],"award-info":[{"award-number":["82200208"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["8247012736"],"award-info":[{"award-number":["8247012736"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["QZ23-6"],"award-info":[{"award-number":["QZ23-6"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["QZ23-4"],"award-info":[{"award-number":["QZ23-4"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["24ZXZSSS00050"],"award-info":[{"award-number":["24ZXZSSS00050"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}]},{"name":"Scientific and Technological Project of Tianjin","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["W2412122"],"award-info":[{"award-number":["W2412122"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["82200208"],"award-info":[{"award-number":["82200208"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["8247012736"],"award-info":[{"award-number":["8247012736"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["QZ23-6"],"award-info":[{"award-number":["QZ23-6"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["QZ23-4"],"award-info":[{"award-number":["QZ23-4"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["24ZXZSSS00050"],"award-info":[{"award-number":["24ZXZSSS00050"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}]},{"name":"Haihe Yingcai (Tianjin) Project","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["W2412122"],"award-info":[{"award-number":["W2412122"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["82200208"],"award-info":[{"award-number":["82200208"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["8247012736"],"award-info":[{"award-number":["8247012736"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["QZ23-6"],"award-info":[{"award-number":["QZ23-6"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["QZ23-4"],"award-info":[{"award-number":["QZ23-4"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["24ZXZSSS00050"],"award-info":[{"award-number":["24ZXZSSS00050"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["TJSJMYXYC-D2-039"],"award-info":[{"award-number":["TJSJMYXYC-D2-039"]}]},{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project grant","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS), is a rare and aggressive form of lymphoma. Its characteristics and treatment outcomes remain poorly understood. Methods: We identified 15 patients who were diagnosed with pcPTCL-NOS between January 2014 and August 2024 at Tianjin Medical University Cancer Institute and Hospital (TMUCIH) in this retrospective study. The clinical and immunophenotypic features, treatment regimens, and outcomes of these patients were investigated. Results: All patients (4 men, 11 women; median age 54 years) presented with skin lesions, including five stage T1, four stage T2 and six stage T3 lesions. pcPTCL-NOS manifests clinically either with solitary or disseminated rapidly growing nodules\/tumors and papules and, less often, ulcers. The lesion sites in patients presenting with solitary\/localized tumors (stage T1 and T2) were the head and limbs, and those in patients presenting with disseminated lesions (stage T3) were the trunk, head, and limbs. The CD4\/CD8 immunophenotypic characteristics were as follows: CD4+\/CD8\u2212 53.33%; CD4+\/CD8+ 26.67%; CD4\u2212\/CD8\u2212 13.33%; and CD4\u2212\/CD8+ 6.67%. One patient had a T follicular helper (TFH) phenotype. Five patients had aberrant expression of the B-cell marker CD20 by tumor cells. All patients received CHOP or CHOP-like regimens as the initial treatment, with three patients undergoing complete lesion resection before chemotherapy, seven patients receiving treatment combined with chidamide (tucidinostat), two patients receiving treatment combined with brentuximab vedotin, two patients receiving treatment combined with mitoxantrone liposomes (Lipo-Mit), three patients receiving treatment combined with radiotherapy, and two patients receiving ASCT after the first-line treatment. The OS rates at 1 year, 2 years, and 3 years were 80%, 77.8%, and 77.8%, respectively; the PFS rates were 60%, 44.4%, and 33.3%, respectively. With a median follow-up of 40 months, the median PFS was 21 months, and the median OS was not reached. Univariate analyses revealed that patients with B symptoms and the CD4\u2212\/CD8\u2212 phenotype had inferior outcomes (p &lt; 0.05). Age, sex, tumor stage, PIT score, Ki-67 index, elevated \u03b22-MG levels, expression of CD20 or PD1, and treatment selection were not associated with the prognosis. A trend of a survival benefit in patients with solitary (T1) tumors compared with patients with disseminated (T2, T3) tumors was observed, suggesting that it is possible to reduce the intensity of treatment in patients with T1 tumors in the future. Conclusions: pcPTCL-NOS is an aggressive but poorly characterized lymphoma that may require early and active systemic treatment. However, for patients with T1 tumors, reducing the intensity of treatment with CHOP should be appropriately considered.<\/jats:p>","DOI":"10.3390\/cancers17101673","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:56:55Z","timestamp":1747299415000},"page":"1673","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Features and Outcomes of Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified, Treated with CHOP-Based Regimens"],"prefix":"10.3390","volume":"17","author":[{"given":"Ge","family":"Hu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, The Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","first-page":"9961","article-title":"Update on primary cutaneous T-cell lymphomas rare subtypes","volume":"16","author":"Berti","year":"2024","journal-title":"Dermatol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dobos, G., Pohrt, A., Ram-Wolff, C., Lebb\u00e9, C., Bouaziz, J.D., Battistella, M., Bagot, M., and de Masson, A. (2020). Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers, 12.","DOI":"10.3390\/cancers12102921"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104126","DOI":"10.1016\/j.lpm.2022.104126","article-title":"Primary cutaneous lymphoma: The 2018 update of the WHO-EORTC classification","volume":"51","author":"Willemze","year":"2022","journal-title":"Presse Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/11.suppl_1.S11","article-title":"EORTC classification for primary cutaneous lymphomas: A comparison with the R.E.A.L. Classification and the proposed WHO Classification","volume":"11","author":"Willemze","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","article-title":"TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jdv.16969","article-title":"Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features","volume":"35","author":"Kempf","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2016.06.011","article-title":"Cutaneous peripheral T-cell lymphoma, not otherwise specifified: A single-center prognostic analysis","volume":"75","author":"Tolkachjov","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6556","DOI":"10.1182\/blood-2022-165489","article-title":"Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified:Characterization of a Large Cohort with Long-Term Outcomes Shows Disparate Outcomes By Body Region Involvement","volume":"140","author":"Stuver","year":"2022","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jaad.2018.09.051","article-title":"Comparative Clinicopathological Analysis of Cutaneous Peripheral T-cell lymphoma, Not Otherwise Specified, According to Primary Tumor Site","volume":"80","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1111\/jdv.14942","article-title":"Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma","volume":"32","author":"Pileri","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5021\/ad.2020.32.4.337","article-title":"A Retrospective Clinicopathologic Study of Korean Patients with Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified at a Single Tertiary Center","volume":"32","author":"Park","year":"2020","journal-title":"Ann. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1080\/10428194.2017.1410886","article-title":"Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: An analysis of 4057 cases from the US National Cancer Database","volume":"59","author":"Su","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","first-page":"553","article-title":"Cutaneous peripheral T-cell lymphomas, unspecified\/NOS and rare subtypes: A heterogeneous group of challenging cutaneous lymphomas","volume":"147","author":"Kempf","year":"2012","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00011-022-01622-x","article-title":"CD20+ T cells: An emerging T cell subset in human pathology","volume":"71","author":"Lee","year":"2022","journal-title":"Inflamm. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mangogna, A., Cox, M.C., Ruco, L., Lopez, G., Belmonte, B., and Di Napoli, A. (2020). Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma Not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. Diagnostics, 10.","DOI":"10.3390\/diagnostics10060341"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomized, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_24","first-page":"514","article-title":"Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin\u2014A monocentric retrospective analysis of twelve patients","volume":"20","author":"Gosmann","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T cell lymphoma: Results of the Ro-CHOP phase III study(conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, J., Sun, X., Gao, G., Yu, L., Wang, J., Qiu, L., Qian, Z., Li, W., and Zhang, H. (2025). CMOEP regimen in the treatment of untreated peripheral T-cell lymphoma: A multicenter, single-arm, phase I study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1551723"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, J., Su, N., Fang, Y., Ma, S., Zhang, Y., Cai, J., Zou, Q., Tian, X., Xia, Y., and Liu, P. (2022). Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.835103"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106705","DOI":"10.1016\/j.leukres.2021.106705","article-title":"Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma","volume":"111","author":"Wang","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"ref_34","first-page":"111","article-title":"Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma","volume":"93","author":"Yumeen","year":"2020","journal-title":"Yale J. Biol. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1673\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:33:16Z","timestamp":1760031196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17101673"],"URL":"https:\/\/doi.org\/10.3390\/cancers17101673","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}